Back to Market返回行情

RVTY Revvity, Inc.

USHealthcare
$112.95+3.29%ClosedMarket Cap: $12.60B

As of 2026-07-09 16:00

Why RVTY matters now

Revvity, Inc. (RVTY) is a US stock in Healthcare. The latest InvestLog snapshot shows $112.95 with +3.29% on the session and $12.60B in market capitalization; recent performance reads 1-month +4.31% and YTD +3.36%.

The latest financial table shown here is Q1 2026, with revenue of $711.1M, net income of $40.7M, and EPS of $0.36. Investors can compare that operating picture with valuation signals such as P/E 40.61 and FCF yield 4.4%.

The latest indexable market news headline is "Revvity to Hold Earnings Call on Tuesday, August 4, 2026" from Business Wire.

Additional event context on this page matters because analyst consensus is Hold with a median target of $111.00; recent insider activity includes Gonzales Anita filing F-InKind; recent congressional disclosure data includes Gilbert Cisneros Purchase. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

40.61

PEG

P/B

1.56

P/S

3.84

EV/EBITDA

17.66

DCF Value

$105.14

FCF Yield

4.4%

Div Yield

0.3%

Margins & Returns

Gross Margin

51.4%

Operating Margin

12.4%

Net Margin

8.3%

ROE

3.3%

ROA

2.0%

ROIC

2.9%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$711.1M$40.7M$0.36
Q4 2025$772.1M$98.4M$0.87
FY 2025$2.86B$241.7M$2.08
Q3 2025$698.9M$46.7M$0.40

Analyst Ratings

Consensus

Hold

Target (Consensus)

$109.83

Target (Median)

$111.00

Target Range

$95.00 - $124.00

Strong Buy: 1Buy: 6Hold: 9Sell: 0Strong Sell: 0
BarclaysEqual Weight
2026-05-07
StifelHold
2026-05-06
TD CowenBuy
2026-05-06
JP MorganNeutral
2026-05-06
BairdOutperform
2026-05-04

Trading Activity

Insider Trades

Gonzales Anitaofficer: Vice President and CAO
Sell2026-06-17
Witz Pascaledirector
Sell2026-05-11
Witz Pascaledirector
Sell2026-05-11
Barrett Peterdirector
Sell2026-05-11
Barrett Peterdirector
Sell2026-05-11

Congress Trades

Gilbert CisnerosBuy
2026-06-09

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

US

Exchange

Beta

1.11

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.